İsrail - İngilizce - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - tablets - dexamethasone 2 mg - dexamethasone - dexamethasone - indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.

İsrail - İngilizce - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - tablets - dexamethasone 0.5 mg - dexamethasone - dexamethasone - indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.

ABD - İngilizce - NLM (National Library of Medicine)

sandoz inc - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 40 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension, usp is indicated as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia, hypercalcemia associated with c

İsrail - İngilizce - Ministry of Health

a.l. medi-market ltd. - dexamethasone phosphate (as sodium) - solution for injection / infusion - dexamethasone phosphate (as sodium) 4 mg / 1 ml - dexamethasone - dexamethasone rompharm is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

İsrail - İngilizce - Ministry of Health

pharmalogic ltd - dexamethasone phosphate (as sodium) - solution for injection / infusion - dexamethasone phosphate (as sodium) 4 mg / 1 ml - dexamethasone - dexamethasone panpharma is indicated in the treatment ofendocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs. ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers. inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis. dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome) haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia nephrotic syndrome of the idiopathic type or that due to lupus erythematosus cerebral oedema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis. infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy) fetal lung maturation chemotherapy – associated nausea and vomiting multiple myeloma – part of chemotherapy protocols (eg vad) prevention and treatment of acute mountain sickness/hace

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

vetoquinol uk limited - marbofloxacin, clotrimazole, dexamethasone (as dexamethasone acetate) - ear drops suspension - unknown - dexamethasone and antiinfectives - canine - antibacterial

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

norbrook laboratories limited - marbofloxacin, clotrimazole, dexamethasone (as dexamethasone acetate) - ear drops suspension - 10.0/3.0 - dexamethasone and antiinfectives - canine - antibacterial

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

norbrook laboratories limited - marbofloxacin, clotrimazole, dexamethasone (as dexamethasone acetate) - ear drops suspension - 10.0/3.0/1 - dexamethasone and antiinfectives - canine - antibacterial

Malta - İngilizce - Medicines Authority

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - dexamethasone - oral solution - dexamethasone 2 mg - corticosteroids for systemic use

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

max health limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: disodium edetate nitrogen propylene glycol sodium hydroxide water for injection - dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid. when so supplemented, dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; · relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available; · primary and secondary adrenocortical insufficiency.